|Bid||120.51 x 500|
|Ask||120.52 x 1000|
|Day's Range||120.23 - 120.82|
|52 Week Range||102.07 - 121.24|
|PE Ratio (TTM)||-62.74|
|Expense Ratio (net)||0.20%|
In 2017, Mylan (MYL) plans to submit BLAs to the FDA for the approval of biosimilars for trastuzumab, pegfilgrastim, bevacizumab, adalimumab, and insulin glargine.
Dividend strategies have drawn increasing interest from investors around the world as central banks have pursued both quantitative and qualitative easy monetary policies, keeping interest rates at what have been exceptionally low levels since 2008. But this preference isn’t entirely new; it has long been known many investors have a preference for cash dividends. From the perspective of classical financial theory, this behavior is an anomaly.
On August 22, 2017, Baxter International entered into a collaboration with ASPEN (American Society for Parenteral and Enteral Nutrition) and launched SmartPN.
Baxter International (BAX) released its 2Q17 earnings results on July 26, beating the analysts' estimates for both revenues and earnings per share.
In fiscal 1Q18, Medtronic's (MDT) Diabetes Group reported revenues of $449 million, which represents a year-over-year sales decline of ~1%.
Medtronic (MDT) reported its fiscal 1Q18 earnings on August 22, 2017. In this series, we'll look at its stock performance since then.
In 2Q17, Merck’s (MRK) Januvia generated revenues of around $948 million, which reflected an ~11% decline on a year-over-year basis and 13% growth on a quarter-over-quarter basis.
On August 21, 2017, ~59% of the analysts tracking Patterson-UTI Energy rated it as a “buy,” ~37% rated it as a “hold,” and only 4% recommended a “sell.”
In 2Q17, Dentsply Sirona’s (XRAY) Technologies business contributed ~44% to the company’s total revenues and registered sales of ~$439 million.
In 2Q17, Amgen’s (AMGN) Kyprolis generated revenues of ~$211 million, which reflected ~23% growth on a YoY (year-over-year) basis and ~11% growth QoQ (quarter-over-quarter). In 2Q17, Kyprolis witnessed ...
Wall Street analysts estimate that Baxter International’s 2Q17 revenues should come in at ~$2.6 billion, a rise of ~0.4% on a year-over-year basis. The company reported revenues of $2.5 billion in 1Q17....
In 2016, Merck’s (MRK) ProQuad reported revenues of ~$495 million, which reflected 9% year-over-year growth.
In 2016, Merck’s Janumet (sitagliptin and metformin HCl) reported revenues of around $2.2 billion, which reflected ~2% YoY growth.
Abbott Laboratories (ABT) reported about $1.6 billion of revenues from its Nutrition segment, representing a YoY (year-over-year) fall of ~1.0%.
Medtronic’s (MDT) Tyrx envelope is an antibacterial and fully-absorbable device that helps prevent surgical site infections.